ARTICLE | Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 4 (OX40; TNFRSF4; CD134)

June 30, 2016 7:00 AM UTC

Mouse studies suggest agonizing OX40 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an agonist anti-OX40 antibody delayed disease onset and decreased the number of interleukin-17 (IL-17)-expressing cells in the CNS and disease progression compared with a control IgG. Next steps include identifying and testing OX40 agonists and IL-17 inhibitors to treat MS in patient-derived cells.

GlaxoSmithKline plc has GSK3174998, a humanized IgG1 mAb agonist of OX40, in Phase I testing to treat HIV/AIDS and solid tumors...